ArticleOncotarget2014
The role of S100A14 in epithelial ovarian tumors.
Article in Oncotarget, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 1 synthesis or guideline pooled it, 29 citations in OpenAlex.
- Prognostic and clinicopathological significance of S100A14 expression in cancer patients: A meta-analysis.Medicine · 2019Pooled it
- PLCD1 expression for early detection and prognosis in High-Grade serous ovarian cancer.BMC cancer · 2025Article
- Article
- Article
- Significance of a calcium-binding protein S100A14 expression in colon cancer progression.Journal of gastrointestinal oncology · 2022Article
- A machine learning approach to identify predictive molecular markers for cisplatin chemosensitivity following surgical resection in ovarian cancer.Scientific reports · 2021Article
- Tetraspanin 1 promotes endometriosis leading to ovarian clear cell carcinoma.Molecular oncology · 2021Article
- S100 family members: potential therapeutic target in patients with hepatocellular carcinoma: A STROBE study.Medicine · 2021Observational
- S100A14 serum level and its correlation with prognostic factors in breast cancer.Journal of the Egyptian National Cancer Institute · 2020Article
- Identification of S100A14 as a metastasis-promoting molecule in a murine organotropic metastasis model.Clinical & experimental metastasis · 2019Article
- Expression profile and functional role of S100A14 in human cancer.Oncotarget · 2019Review
- S100A14 Is Increased in Activated NK Cells and Plasma of HIV-Exposed Seronegative People Who Inject Drugs and Promotes Monocyte-NK Crosstalk.Journal of acquired immune deficiency syndromes (1999) · 2019Article
- Prognostic values of S100 family members in ovarian cancer patients.BMC cancer · 2018Article
- Establishment of five immortalized human ovarian surface epithelial cell lines via SV40 T antigen or HPV E6/E7 expression.PloS one · 2018Article
- Chromosome 1q21.3 amplification is a trackable biomarker and actionable target for breast cancer recurrence.Nature medicine · 2017Article
- A signal-based method for finding driver modules of breast cancer metastasis to the lung.Scientific reports · 2017Article
- Calcium-binding protein S100A14 induces differentiation and suppresses metastasis in gastric cancer.Cell death & disease · 2017Article
- Accumulation of cytoplasmic Cdk1 is associated with cancer growth and survival rate in epithelial ovarian cancer.Oncotarget · 2016Article
- KCNN4 and S100A14 act as predictors of recurrence in optimally debulked patients with serous ovarian cancer.Oncotarget · 2016Article
- SYF2 is upregulated in human epithelial ovarian cancer and promotes cell proliferation.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 4 institutions in 2 countries.
Funding
Abstract
S100A14 is an EF-hand calcium-binding protein that has been reported to be involved in the progression of many malignancies. However, its role in ovarian cancer has not yet been clarified. In this study, we investigated the significance of S100A14 expression in epithelial ovarian cancers (EOCs) as well as it's mechanism of action. On both RNA and protein levels, S100A14 was overexpressed in transformed cells. Immunohistochemical staining demonstrated that S100A14 expression was associated with advanced stage (P<0.001) and poor tumor grade (P<0.001). Moreover, S100A14 overexpression was an independent prognostic factor for overall survival (HR = 4.53, P = 0.029). We also investigated S100A14's functional role by employing lentiviral-mediated overexpression and knockdown in EOC cells. S100A14 overexpression promoted cell proliferation, tumorigenesis, migration, and invasion, whereas S100A14 knockdown inhibited these properties. TOV112D cells that overexpressed S100A14 also exhibited greater tumor growth potential in xenografted mice. S100A14 promoted such a malignant phenotype in EOC cells through the PI3K/Akt pathway. Taken together, our data indicate that S100A14 has a crucial role in EOC progression, and its overexpression is associated with poor prognosis. Further study of S100A14's molecular mechanisms may lead to the development of a novel therapeutic target for ovarian cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.